• Explore /
  • Poster
  • / Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.

Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.

Abstract Poster

Authors

Andrew Weickhardt

Andrew James Weickhardt

Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, VIC, Australia

Andrew James Weickhardt , Michiel Simon Van Der Heijden , Arjun Vasant Balar , Shahrokh F. Shariat , Neal D. Shore , Xiao Fang , James Luke Godwin , Ekta Kapadia , Jeff M. Michalski , Nicholas D. James

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04241185

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS508)

DOI

10.1200/JCO.2021.39.6_suppl.TPS508

Abstract #

TPS508

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Arjun Vasant Balar

First Author: Shilpa Gupta

First Author: Arlene O. Siefker-Radtke

First Author: Andrew James Weickhardt